Glenn Kawasaki, Ph.D.
Chief Executive Officer
Dr. Kawasaki has 24 years of experience in start-up biotechnology companies. He was the first scientist (1981) and chair of the Science Board at ZymoGenetics, Inc., today a one-billion-dollar public corporation. He has a Ph.D. in Genetics (1979), an M.B.A. (1986), and a J.D. (1995) each from the University of Washington. Dr. Kawasaki was a research fellow at Harvard Medical School from 1979-81 and was an undergraduate at U.C. Berkeley, where he earned a B.S. in Genetics and an A.B. in Zoology. In 1989 he founded Aptein, Inc., which was based on Dr. Kawasaki's invention now known as "ribosome display" for engineering antibodies and other proteins. He was the President, CEO, and Research Director of this Seattle company. Aptein was sold to Cambridge Antibody Technology, a U.K. firm, in 1998. In 1999, Dr. Kawasaki founded Catch Incorporated, which developed and now sells a novel test for homocysteine, a compound linked to cardiovascular diseases, Alzheimer's Disease, glaucoma, and other ailments. Dr. Kawasaki remains an executive officer and director of Catch but is not an employee of the Bothell, WA, firm. He is a founder and director of Sound Pharmaceuticals, another Seattle start-up (2001), which is focused on preventing and restoring hearing loss. Dr. Kawasaki has 14 U.S. patents and over a hundred foreign related patents. Dr. Kawasaki is also a Vice President of the Pacific Northwest Ballet Company in Seattle.
J. Scott Tarrant
VP Corporate Development
Scott has over twenty years of technical sales, marketing and business development experience with companies ranging from early stage start-ups to large ($1.0B plus) publicly traded entities. Most recently he served as Executive Vice President of Global Sales and Marketing for UK based Xceleron Ltd, a specialty CRO utilizing accelerator mass spectrometry (AMS) to obtain early ADME and PK data in exploratory clinical development. Scott established Xcelerons US subsidiary in Maryland, negotiated state, local and private funding support, and led the rapid growth in sales culminating in the build-out of state-of-the-art research facilities in early 2008. Prior to Xceleron, Scott led a sales team of both genomics and preclinical CRO services at Gene Logic Inc. who acquired TherImmune Research Corporation in 2003. Scott joined TherImmune in early 1999 as the company was being formed. At TherImmune he served as VP Sales and Marketing leading the organization to annual sales of nearly $30 million in preclinical services prior to its acquisition. Scott was formerly District Sales Manager for Nalco Chemical Company in Washington, DC. Prior to his 10-year sales/management career at Nalco, he served four years in various leadership positions as a combat engineer officer in the United States Army. Scott received his B.S. in Biology from SUNY College of Environmental Science and Syracuse University and is a 2008 graduate of the International Executive Program in General Management at INSEAD, Fontainebleau, France and Singapore.
Ugo Zoppi, Ph.D.
Director, AMS Laboratory
Dr. Zoppi is Director of Accium's Accelerator Mass Spectrometry Facility and is responsible for all AMS operations, maintenance, routine measurements, as well as development of new AMS methodologies. Dr. Zoppi is a recognized expert in the field of Accelerator Mass Spectrometry with over 40 AMS publications and several AMS chapters to his name. Dr. Zoppi joined Accium in 2006, bringing with him over 15 years of operations and management experience from three world-class AMS facilities (Zurich, Tokyo and Sydney) where he was responsible for the quality of all radiocarbon measurements and operations. Dr. Zoppi obtained his Ph.D. degree from Department of Nuclear Physics and Astronomy, Swiss Federal Institute of Technology (ETH) in Zürich in the laboratory of Professor Dr. W. Wölfli and Dr. M. Suter. His Ph.D. thesis title was "Isobar suppression in Accelerator Mass Spectrometry". Dr. Zoppi also holds a degree in Frontline Management from the Australian Institute of Management (AIM) with a degree focus in Team and Business Unit Performance. He has language proficiency in Italian (native), English, French, German, Japanese (basic) and Spanish (basic).
Director, Bioanalytical Services
Julie Zalikowski joined Accium in late 2012, bringing with her over 15 years of experience within the pharmaceutical bioanalytical industry, including leadership positions at Amgen, Novartis Diagnostics and AstraZeneca. Julie's DMPK experience covers a wide range of activities, from small molecule development at AstraZeneca-Wilmington, which included development of Crestor, to large molecule development and CRO management at Amgen-Seattle. In addition to her strong analytical and scientific skills, Julie has considerable experience in project management. She holds a certificate in Biotechnology Project Management, further solidifying her skills as a Study Director and Director of Accium’s Bioanalytical Group.
Quality Assurance Officer, Vice President
Ms. Alford-Cassel is Accium's Quality Assurance Officer. She brings over 20 years of QA leadership experience from the pharmaceutical and medical device industry. She has led the Quality Assurance efforts in cross-functional product development teams and has successfully developed and implemented Quality Systems in several start-up environments.